# A Study of IMC-001 In Patients With Metastatic Or Locally Advanced TMB-H Solid Tumor

Source: https://onco.cc/trials/nct06365840/  
OnCo record `nct06365840` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of IMC-001 in advanced solid tumours, run by ImmuneOncia Therapeutics Inc., now recruiting.

## Summary

A Study of IMC-001 In Patients With Metastatic Or Locally Advanced TMB-H Solid Tumor is a phase 2 interventional study registered as NCT06365840 by ImmuneOncia Therapeutics Inc., with 30 participants planned, started 2025-01-13 and due to reach its primary completion in 2027-06-30. Interventions recorded: IMC-001.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06365840
- Phase: 2
- Setting: PHASE 2 STUDY OF IMC-001 IN PATIENTS WITH METASTATIC OR LOCALLY ADVANCED TMB-H SOLID TUMOR
- Sponsor: ImmuneOncia Therapeutics Inc.
- Enrolled: 30

## Sources

- ClinicalTrials.gov NCT06365840: https://clinicaltrials.gov/study/NCT06365840

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- companies: [ImmuneOncia Therapeutics](https://onco.cc/companies/immuneoncia-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/nct06365840.json